Abstract
The peptides Api88 and Onc72 are highly efficient to treat Escherichia coli bacteremia in mice. Here we extended the animal studies to a systemic murine infection model using a multidrug-resistant carbapenemase-producing Klebsiella pneumoniae clinical isolate. When administered intraperitoneally three times at 2.5, 5 and 10 mg/kg bodyweight to CD-1 mice infected with a KPC-producing K. pneumoniae strain, both Api88 and Onc72 reduced the bacterial counts by at least 5 log10 units, indicating that both peptides are active in vivo. Both peptide treatments increased significantly the survival rates and average survival times compared to untreated animals for all doses except for the highest dose of Onc72. This dose reduced the bacterial counts so fast that it most likely induced a sudden release of large amounts of toxic materials from the killed bacteria reducing the survival time even below that of untreated mice. In conclusion, both peptides were efficient in the lethal murine K. pneumoniae infection model, but the treatment protocol (i.e. dose and time points) has to be further optimized based on future pharmacokinetic studies.
Keywords: Antibacterial peptides, Api88, Klebsiella pneumoniae carbapenemase (KPC), murine infection model, Onc72.
Protein & Peptide Letters
Title:In Vivo Activity of Optimized Apidaecin and Oncocin Peptides Against a Multiresistant, KPC-Producing Klebsiella pneumoniae Strain
Volume: 21 Issue: 4
Author(s): Eszter Ostorhazi, Eva Nemes-Nikodem, Daniel Knappe and Ralf Hoffmann
Affiliation:
Keywords: Antibacterial peptides, Api88, Klebsiella pneumoniae carbapenemase (KPC), murine infection model, Onc72.
Abstract: The peptides Api88 and Onc72 are highly efficient to treat Escherichia coli bacteremia in mice. Here we extended the animal studies to a systemic murine infection model using a multidrug-resistant carbapenemase-producing Klebsiella pneumoniae clinical isolate. When administered intraperitoneally three times at 2.5, 5 and 10 mg/kg bodyweight to CD-1 mice infected with a KPC-producing K. pneumoniae strain, both Api88 and Onc72 reduced the bacterial counts by at least 5 log10 units, indicating that both peptides are active in vivo. Both peptide treatments increased significantly the survival rates and average survival times compared to untreated animals for all doses except for the highest dose of Onc72. This dose reduced the bacterial counts so fast that it most likely induced a sudden release of large amounts of toxic materials from the killed bacteria reducing the survival time even below that of untreated mice. In conclusion, both peptides were efficient in the lethal murine K. pneumoniae infection model, but the treatment protocol (i.e. dose and time points) has to be further optimized based on future pharmacokinetic studies.
Export Options
About this article
Cite this article as:
Ostorhazi Eszter, Nemes-Nikodem Eva, Knappe Daniel and Hoffmann Ralf, In Vivo Activity of Optimized Apidaecin and Oncocin Peptides Against a Multiresistant, KPC-Producing Klebsiella pneumoniae Strain, Protein & Peptide Letters 2014; 21 (4) . https://dx.doi.org/10.2174/09298665113206660107
DOI https://dx.doi.org/10.2174/09298665113206660107 |
Print ISSN 0929-8665 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5305 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Infection, Infectious Agents and Vascular Disease
Reviews on Recent Clinical Trials Chloramphenicol Enhances IDUA Activity on Fibroblasts from Mucopolysaccharidosis I Patients
Current Pharmaceutical Biotechnology Immunology and Epilepsy: Clinical and Experimental Evidence
Current Immunology Reviews (Discontinued) Comparative Time-Kill Study of Doxycycline, Tigecycline, Cefazolin and Vancomycin Against Several Clones of Staphylococcus aureus
Current Clinical Pharmacology Novelty in Inflammation and Immunomodulation in Migraine
Current Pharmaceutical Design A Potential Andrographolide Analogue against the Replication of Herpes Simplex Virus Type 1 in Vero Cells
Medicinal Chemistry Community-Acquired Pneumonia in Children
Recent Patents on Inflammation & Allergy Drug Discovery A Case of Neurosarcoidosis Mimicking Brain Tumor
Current Medical Imaging Anti-Biofilm Strategies and the Need for Innovations in Wound Care
Recent Patents on Anti-Infective Drug Discovery Non-Steroidal Anti-Inflammatory Drugs used as a Treatment Modality in Subarachnoid Hemorrhage
Current Drug Safety Editorial
Current Medical Imaging An Association of Virus Infection with Type 2 Diabetes and Alzheimer’s Disease
CNS & Neurological Disorders - Drug Targets Water and Ion Channels: Crucial in the Initiation and Progression of Apoptosis in Central Nervous System?
Current Neuropharmacology Bacterial Protein Microarrays for Diagnosis of Infectious Diseases
Current Immunology Reviews (Discontinued) Basic Approaches in Therapy of Multiple Sclerosis (MS) and Related Diseases: Current Achievement and Prospective
Central Nervous System Agents in Medicinal Chemistry Nanomedicines as Cancer Therapeutics: Current Status
Current Cancer Drug Targets Clinical Pharmacokinetics of Systemically Administered Antimycotics
Current Clinical Pharmacology Functional Chemical Groups that May Likely Become a Source for the Synthesis of Novel Central Nervous System (CNS) Acting Drugs
Central Nervous System Agents in Medicinal Chemistry Progenitor Cell Types in HIV-1 Infection: Bioactivity and Emerging Targets for Treatment
Current HIV Research The Immunocompromised Host: Immune Alterations in Splenectomized Patients and Clinical Implications
Current Pharmaceutical Design